Published in Curr Opin Neurol on October 01, 2012
The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am J Hum Genet (2013) 1.25
DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle. Hum Mol Genet (2014) 1.06
Disruption of long-range gene regulation in human genetic disease: a kaleidoscope of general principles, diverse mechanisms and unique phenotypic consequences. Hum Genet (2014) 0.91
Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy. Clin Epigenetics (2015) 0.88
Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease. Antioxid Redox Signal (2014) 0.86
CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy. Mol Ther (2015) 0.84
Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation. Ann Clin Transl Neurol (2015) 0.79
miRNA expression in control and FSHD fetal human muscle biopsies. PLoS One (2015) 0.76
A novel tRNA variable number tandem repeat at human chromosome 1q23.3 is implicated as a boundary element based on conservation of a CTCF motif in mouse. Nucleic Acids Res (2014) 0.75
Facioscapulohumeral muscular dystrophy: Are telomeres the end of the story? Rare Dis (2013) 0.75
Meeting Report: New Directions in the Biology and Disease of Skeletal Muscle 2014. J Neuromuscul Dis (2014) 0.75
Molecular mechanisms of long noncoding RNAs. Mol Cell (2011) 11.44
The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science (2007) 9.36
Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet (2006) 6.43
Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet (1992) 5.12
A unifying genetic model for facioscapulohumeral muscular dystrophy. Science (2010) 4.87
Studies in disorders of muscle. II Clinical manifestations and inheritance of facioscapulohumeral dystrophy in a large family. Ann Intern Med (1950) 3.75
Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet (2003) 3.60
Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell (2002) 3.56
Antisense transcription controls cell fate in Saccharomyces cerevisiae. Cell (2006) 3.49
DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci U S A (2007) 3.32
Genetics and epigenetics of the multifunctional protein CTCF. Curr Top Dev Biol (2008) 3.01
Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene (1999) 3.00
Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet (2010) 2.95
Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet (2009) 2.90
The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord (2007) 2.85
Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat (2009) 2.84
A structural-maintenance-of-chromosomes hinge domain-containing protein is required for RNA-directed DNA methylation. Nat Genet (2008) 2.74
Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet (1994) 2.60
RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet (2009) 2.51
Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat Genet (2002) 2.42
A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. Cell (2012) 2.29
DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell (2011) 2.17
Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology (2010) 2.01
Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am J Hum Genet (2012) 1.88
Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med (2011) 1.80
Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy. Am J Hum Genet (2004) 1.72
Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26: implications for genetic counselling and etiology of FSHD1. Hum Mol Genet (1996) 1.71
Cutting edge: human beta defensin 3--a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol (2006) 1.67
Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. Mutat Res (2008) 1.45
The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One (2011) 1.45
Facioscapulohumeral muscular dystrophy in the Dutch population. Muscle Nerve Suppl (1995) 1.43
Physical mapping evidence for a duplicated region on chromosome 10qter showing high homology with the facioscapulohumeral muscular dystrophy locus on chromosome 4qter. Eur J Hum Genet (1995) 1.43
Complete allele information in the diagnosis of facioscapulohumeral muscular dystrophy by triple DNA analysis. Ann Neurol (2001) 1.42
Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD. Neurology (2007) 1.41
DXZ4 chromatin adopts an opposing conformation to that of the surrounding chromosome and acquires a novel inactive X-specific role involving CTCF and antisense transcripts. Genome Res (2008) 1.40
The FSHD-linked locus D4F104S1 (p13E-11) on 4q35 has a homologue on 10qter. Muscle Nerve Suppl (1995) 1.39
The D4Z4 macrosatellite repeat acts as a CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral dystrophy. PLoS Genet (2009) 1.37
Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet (2009) 1.35
Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol (2011) 1.31
Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord (2009) 1.30
Human β-defensin 3 affects the activity of pro-inflammatory pathways associated with MyD88 and TRIF. Eur J Immunol (2011) 1.27
Chemokine expression and control of muscle cell migration during myogenesis. J Cell Sci (2010) 1.26
Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol (2010) 1.26
Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol (2010) 1.25
Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve Suppl (1995) 1.23
Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord (2001) 1.19
A nuclear matrix attachment site in the 4q35 locus has an enhancer-blocking activity in vivo: implications for the facio-scapulo-humeral dystrophy. Genome Res (2007) 1.17
CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol (2010) 1.16
A large patient study confirming that facioscapulohumeral muscular dystrophy (FSHD) disease expression is almost exclusively associated with an FSHD locus located on a 4qA-defined 4qter subtelomere. J Med Genet (2006) 1.14
Expression, tandem repeat copy number variation and stability of four macrosatellite arrays in the human genome. BMC Genomics (2010) 1.08
The magnetic resonance imaging spectrum of facioscapulohumeral muscular dystrophy. Muscle Nerve (2012) 1.06
The RS447 human megasatellite tandem repetitive sequence encodes a novel deubiquitinating enzyme with a functional promoter. Genomics (2000) 1.04
A functional role for 4qA/B in the structural rearrangement of the 4q35 region and in the regulation of FRG1 and ANT1 in facioscapulohumeral dystrophy. PLoS One (2008) 1.01
RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. Mol Ther (2012) 1.00
Induction of myogenic differentiation by SDF-1 via CXCR4 and CXCR7 receptors. Muscle Nerve (2010) 0.94
Improved characterization of FSHD mutations. Ann Genet (2001) 0.94
Asymmetric bidirectional transcription from the FSHD-causing D4Z4 array modulates DUX4 production. PLoS One (2012) 0.90
Early onset facioscapulohumeral muscular dystrophy. Muscle Nerve Suppl (1995) 0.87
DNaseI hypersensitivity at gene-poor, FSH dystrophy-linked 4q35.2. Nucleic Acids Res (2009) 0.85
Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med (2004) 5.59
CTCF physically links cohesin to chromatin. Proc Natl Acad Sci U S A (2008) 4.89
A unifying genetic model for facioscapulohumeral muscular dystrophy. Science (2010) 4.87
MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol (2005) 4.57
Genome-wide MyoD binding in skeletal muscle cells: a potential for broad cellular reprogramming. Dev Cell (2010) 4.50
Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell (2005) 4.07
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression. Mol Cell (2002) 3.29
Pbx marks genes for activation by MyoD indicating a role for a homeodomain protein in establishing myogenic potential. Mol Cell (2004) 3.15
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol (2005) 3.07
Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet (2010) 2.95
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol (2008) 2.95
MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol (2006) 2.85
Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat (2009) 2.84
Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet (2012) 2.82
Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther (2007) 2.76
Essential role for Dicer during skeletal muscle development. Dev Biol (2007) 2.76
Loss of cell polarity causes severe brain dysplasia in Lgl1 knockout mice. Genes Dev (2004) 2.55
MyoD targets chromatin remodeling complexes to the myogenin locus prior to forming a stable DNA-bound complex. Mol Cell Biol (2005) 2.55
Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A (2006) 2.52
RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet (2009) 2.51
Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet (2003) 2.50
Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest (2002) 2.48
Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination. J Cell Biol (2007) 2.44
Global and gene-specific analyses show distinct roles for Myod and Myog at a common set of promoters. EMBO J (2006) 2.38
An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet (2007) 2.25
An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord (2007) 2.17
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet (2002) 2.17
DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell (2011) 2.17
A MyoD-generated feed-forward circuit temporally patterns gene expression during skeletal muscle differentiation. Genes Dev (2004) 2.16
Regulation of thalamocortical patterning and synaptic maturation by NeuroD2. Neuron (2006) 2.15
p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specific genes during differentiation. Nat Struct Mol Biol (2007) 2.03
Widespread and nonrandom distribution of DNA palindromes in cancer cells provides a structural platform for subsequent gene amplification. Nat Genet (2005) 1.99
Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet (2011) 1.97
Differential genomic targeting of the transcription factor TAL1 in alternate haematopoietic lineages. EMBO J (2010) 1.82
Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med (2011) 1.80
The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell (2006) 1.78
Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation (2005) 1.77
CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination. PLoS Genet (2008) 1.72
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther (2007) 1.70
Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther (2007) 1.68
BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med (2003) 1.67
Characterization of microRNAs involved in embryonic stem cell states. Stem Cells Dev (2010) 1.62
Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord (2003) 1.56
Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol (2005) 1.53
Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta (2006) 1.52
Frequent endonuclease cleavage at off-target locations in vivo. Mol Ther (2010) 1.52
Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet (2005) 1.51
Muscle growth after postdevelopmental myostatin gene knockout. Am J Physiol Endocrinol Metab (2006) 1.49
CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron (2011) 1.49
Thyroid hormone-regulated enhancer blocking: cooperation of CTCF and thyroid hormone receptor. EMBO J (2003) 1.49
Genetic and epigenetic determinants of neurogenesis and myogenesis. Dev Cell (2012) 1.47
Pbx homeodomain proteins direct Myod activity to promote fast-muscle differentiation. Development (2007) 1.47
Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther (2011) 1.42
Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum Gene Ther (2007) 1.42
Intrastrand annealing leads to the formation of a large DNA palindrome and determines the boundaries of genomic amplification in human cancer. Mol Cell Biol (2007) 1.36
Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level. Eur J Hum Genet (2009) 1.33
Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol (2011) 1.32
Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology (2012) 1.31
Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol (2011) 1.31
Short inverted repeats initiate gene amplification through the formation of a large DNA palindrome in mammalian cells. Proc Natl Acad Sci U S A (2002) 1.30
DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proc Natl Acad Sci U S A (2009) 1.26
The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am J Hum Genet (2013) 1.25
Facioscapulohumeral dystrophy. Phys Ther (2007) 1.22
Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22
Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve (2013) 1.20
Analysis of allele-specific RNA transcription in FSHD by RNA-DNA FISH in single myonuclei. Eur J Hum Genet (2009) 1.20
Sex-related differences in gene expression in human skeletal muscle. PLoS One (2008) 1.20
Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. PLoS Genet (2013) 1.19
Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Hum Mol Genet (2008) 1.19
The dosage of the neuroD2 transcription factor regulates amygdala development and emotional learning. Proc Natl Acad Sci U S A (2005) 1.19
MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev (2009) 1.18
Epigenetics of a tandem DNA repeat: chromatin DNaseI sensitivity and opposite methylation changes in cancers. Nucleic Acids Res (2008) 1.14
Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology (2013) 1.14
Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther (2012) 1.13
Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors. Mol Cell Biol (2012) 1.12
In vitro transcription system delineates the distinct roles of the coactivators pCAF and p300 during MyoD/E47-dependent transactivation. Proc Natl Acad Sci U S A (2004) 1.12
Gene expression during normal and FSHD myogenesis. BMC Med Genomics (2011) 1.12
Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol Ther (2009) 1.11
DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis. PLoS Genet (2013) 1.11
A focal domain of extreme demethylation within D4Z4 in FSHD2. Neurology (2013) 1.08